VAC-3S

BIOLOGICAL3 trials

Sponsors

InnaVirVax

Conditions

HIVHIV-1 Infection

Phase 1

Phase I/IIa Dose-escalation Clinical Study of VAC-3S

CompletedNCT01549119

InnaVirVaxHIV-1 Infection

Start: 2012-02-29End: 2014-12-31Updated: 2015-02-02

Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1

Start: 2015-04-30End: 2017-04-30Target: 15Updated: 2016-06-17

Phase 2

Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection

Start: 2014-01-31End: 2016-11-30Target: 90Updated: 2016-06-17